SGLT2 inhibitors may reduce the risk of acute myocardial infarction via mechanisms responsible for attenuating neurohormonal activation, cardiomyocyte necrosis, and reperfusion injury. This evidence concerns the gene SLC5A2 and acute myocardial infarction.